Diseases [C] » Digestive System Diseases [C06] » Liver Diseases
Hierarchy View
Subtype Terms (24)
alpha 1-Antitrypsin Deficiency
24 drugs (13 approved, 11 experimental)
Chemical and Drug Induced Liver Injury
31 drugs (24 approved, 7 experimental)
Cholestasis, Intrahepatic
5 drugs (4 approved, 1 experimental)
Fatty Liver
82 drugs (37 approved, 45 experimental)
Focal Nodular Hyperplasia
1 experimental drug
Hepatic Insufficiency
56 drugs (35 approved, 21 experimental)
Hepatic Veno-Occlusive Disease
3 approved drugs
Hepatitis
39 drugs (25 approved, 14 experimental)
Hepatolenticular Degeneration
18 drugs (10 approved, 8 experimental)
Hepatomegaly
5 approved drugs
Hepatopulmonary Syndrome
6 approved drugs
Hepatorenal Syndrome
9 drugs (8 approved, 1 experimental)
Hypertension, Portal
66 drugs (40 approved, 26 experimental)
Liver Abscess
5 approved drugs
Liver Cirrhosis
263 drugs (155 approved, 108 experimental)
Liver Diseases, Alcoholic
25 drugs (10 approved, 15 experimental)
Liver Neoplasms
352 drugs (150 approved, 202 experimental)
Zellweger Syndrome
7 drugs (6 approved, 1 experimental)
Approved Indicated Drugs (11)
Phase 3 Indicated Drugs (23)
Phase 2 Indicated Drugs (45)
Phase 1 Indicated Drugs (213)
Other Experimental Indicated Drugs (34)
Organization Involved with Phase 4 Indications (152)
All India Institute of Medical Sciences
Belupo d.d., Koprivnica, Croatia
CEINGE - Biotecnologie Avanzate, Napoli, Italia
Chinese Academy of Medical Sciences
Clinical Hospital Centre Rijek, Croatia
Federal Ministry of Health, Germany
Huntington Medical Research Institutes
Icahn School of Medicine at Mount Sinai
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Katholieke Universiteit Leuven
Kuhnil Pharmaceutical Co., Ltd.
Medical University of South Carolina
National Health Service, United Kingdom
National Institute of Allergy and Infectious Diseases (NIAID)
National University of Ireland
Oregon Health and Science University
People's Liberation Army of China
Samil Pharmaceutical Co., Ltd.
Second Military Medical University
Shenzhen Kangtai Biological Products Co., LTD
State University of New York, Syracuse
Taipei Veteran General hospital
The Deutsche Diabetes Forschungsgesellschaft e.V.
The University of Texas, Dallas
Universidad Autonoma de Barcelona
Universidad Complutense de Madrid
Université catholique de Louvain
Organization Involved with Phase 3 Indications (75)
Asian Institute of Gastroenterology
ASPEN Rhoads Research Foundation
Bambino Gesù Hospital and Research Institute
Beijing Trendful Kangjian Medical Information Consulting Limited Company
Gottfried Wilhelm Leibniz Universität Hannover
Hamilton Health Sciences Corporation
Huazhong University of Science and Technology
Indian Council of Medical Research
Institute of Liver and Biliary Sciences, India
Joint Clinical Research Centre, Kampala, Uganda
Kapiolani Medical Center For Women & Children
Nanyang Technological University
National Center for Research Resources (NCRR)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
National Nutrition and Food Technology Institute
National University of Singapore
NO.6 People's Hospital of Hangzhou
Postgraduate Institute of Medical Education and Research
Rio de Janeiro State University
Organization Involved with Phase 2 Indications (167)
Antipodean Pharmaceuticals, Inc.
Aristotle University of Thessaloniki
Beilinson Hospital, Petach Tikva
Childhood Liver Disease Research and Education Network
Children's Memorial Health Institute, Poland
French National Agency for Research on AIDS and Viral Hepatitis
Grupo Mexicano para el Estudios de las Enfermedades Hepaticas
HemCon Medical Technologies, Inc
Holy Family Hospital, Nazareth, Israel
Jiangsu Nhwa Pharmaceutical Co., Ltd.
Kashan University of Medical Sciences
KTH Royal Institute of Technology
Medical University of Bialystok
Memorial Sloan-Kettering Cancer Center
Metropolitan Liver Diseases/ Gastroenterology Center
National Cancer Institute (NCI)
National Center for Complementary and Integrative Health (NCCIH)
National Institute for Health Research, United Kingdom
National Institutes of Health (NIH)
Orlando Clinical Research Center
Pediatric Municipal Hospital of Rzeszow, Poland
Queen Elizaberth Hospital, Sabah
Radiological Society of North America
Russian Academy of Medical Sciences
Sahlgrenska University Hospital, Sweden
Shanghai Municipal Science and Technology Commission
Silesian University of Medicine
Singapore Bioimaging Consortium
Singapore Clinical Research Institute
Singapore Institute for Clinical Sciences
St. Petersburg State Public Medical Institution
Sultanah Bahiyah Hospital, Alor Star
TaiGen Biotechnology Co., Ltd.
Tengku Ampuau Afzan Hospital, Kuantan
University of California, San Diego
University of Electronic Science and Technology of China
University of North Carolina at Chapel Hill
Veterans Medical Research Foundation
Organization Involved with Phase 1 Indications (120)
Autonomous University of Madrid
Boryung Pharmaceutical Company
City of Hope National Medical Center
Multidisciplinary Association for Psychedelic Studies
Organization Involved with Other Experimental Indications (66)
American College of Gastroenterology
Bogomolets National Medical University
Canadian Institutes of Health Research (CIHR)
Children's Hospital Los Angeles
Children's Medical Center Dallas
Chinese University of Hong Kong
Composite Interceptive Med-Science
Daiwa Pharmaceutical Corporation
Danish Council for Independent Research
Doctors Hospital at Renaissance
Federal University of Health Science of Porto Alegre
Federal University of Minas Gerais
Guangdong Pharmaceutical University
Instituto Mexicano del Seguro Social
National Natural Science Foundation of China
Sir Salimullah Medical College
State University of New York, Brooklyn
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
